Key COVID-19 response policies and descriptions
| Policies | Subpolicies | Descriptions |
| Test-trace-isolate policy | Community testing | A combination of active testing within the community to identify positive cases, establish the chain of transmission and isolate positive cases to prevent further spread. |
| Isolation of positive cases (or suspected positive cases) | Policy to require mild/moderate positive patients to be isolated either in their homes or in care facilities. This includes policy requiring international travellers to observe self-isolation for a fixed period of time. Where extensive contact tracing is available, people who have come into close contacts with patients who are COVID-19 positive are also required to serve stay-at-home notice or quarantine orders. | |
| Contact tracing initiatives | Government or state’s initiatives to identify close contacts of COVID-19 cases to prevent the spread. | |
| Travel restriction | – | International travel restriction implemented by the government to ban, limit or restrict international travellers. |
| Compulsory face masks and improved hygiene practices | – | Requirement to wear face masks or facial coverings when in public spaces. |
| Social distancing | As-needed workplaces and schools closures | Requirement to shut down workplaces or educational facilities when a cluster or a number of cases are detected, in order to test exposed individuals and disinfect the affected locations. |
| Compulsory work-from-home policies | This policy is complementary with social lockdown. Companies are to continue its operation with their staff working from home. This policy may remain in place even after social lockdown has been lifted. | |
| Physical distancing | Sets of policies requiring social gathering to maintain minimum distance (1 to 2 m) between members when outside of their homes or residences. This policy is often accompanied by restricting service capacity of business, mainly retails, malls and personal services to prevent overcrowding. | |
| Dexamethasone therapy | – | Intravenous dexamethasone 6 mg one time per day for up to 10 days among patients with severe and very severe symptoms. |
| Remdesivir therapy | – | Intravenous remdesivir 200 mg on day 1, followed by 100 mg one time per day up to day 10 among patients with severe and very severe symptoms. |
| Vaccination | – | Vaccination against SARS-CoV-2. |